iHAS is an organisation providing services and products in the medical field. We provide medical tourism and oncotests for breast, colon and prostate cancer.
Our Mission is to help improve the health and well-being of Bulgarian patients by providing access to high-quality medical services and products, as well as specialized medical care in Bulgaria and abroad
iHAS Strategy involves the identification of innovative biomedical products/services that are not available to the Bulgarian patients yet.
The iHAS Portfolio includes:
- Sale of genetic analysis assays
- Sale of genetic analysis to determine the risk of developing certain oncology diseases
- Social network / Web-based registry for patients suffering from certain type of disease or taking certain types of medication
- Medical Tourism
- Registration and distribution of drugs and medical devices
George Pishtiyski
Founder
George Pishtiyski`s valuable experience was gained through work at key positions in Farmacia AD, Balkanpharma AD, Actavis group, now part of the Watson Pharmaceuticals, Inc. Mr. Pishtiyski has been a leading member in a number of Pharmaceutical projects. He has an extensive experience in developing and implementing of business strategies aimed at maximizing market share and achieving sales objectives as well as responding to opportunities and threats in the Global market.
Dr. Ivanka Dimova
Consultant
Dr. Ivanka Dimova works at the Department of Medical Genetics at the Medical University – Sofia 2001 acquired Doctorate of Medicine (Genetics) in 2006 after a successful thesis on “Genetic characterization of different types of ovarian tumors.” Much of her thesis developed into one of the leading centers for cancer research – Centre de recherché en cancerologie, University of Montpellier, France.
Partners
Genomic Health, Inc. (NASDAQ: GHDX) is a global health company that provides actionable genomic information to personalize genomic health decisions. The company’s lead product, the Oncotype DX breast cancer test, has been shown to predict the likelihood of as well as recurrence in invasive and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II disease and appropriate stage III patients.
Multigene Expression Tests – Diagnostic tests for cancer allowing physicians and patients to make individualized treatment decisions. The pioneering work of Genomic Health in molecular diagnostics has led to the commercialization of clinically validated assays (tests) that provide individualized tumor information for patients and physicians for consideration as they make important treatment decisions. Тo learn more about the Oncotype DX tests for DCIS, breast & colon cancer, please visit oncotypeDX.com.